HEALTHSTAT NEWS
STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
An FDA advisory panel recommended allowing compounding pharmacies to produce peptides like BPC-157 and TB-500, despite FDA staff concerns about safety and efficacy. Sanofi's long-acting insulin pen, Lantus Solostar, faces supply shortages due to increased demand, causing challenges for diabetes patients.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
- STAT+: Popular insulin product enters shortage as other pens leave market
- STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
- STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
- STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more